JPWO2020117772A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020117772A5 JPWO2020117772A5 JP2021531983A JP2021531983A JPWO2020117772A5 JP WO2020117772 A5 JPWO2020117772 A5 JP WO2020117772A5 JP 2021531983 A JP2021531983 A JP 2021531983A JP 2021531983 A JP2021531983 A JP 2021531983A JP WO2020117772 A5 JPWO2020117772 A5 JP WO2020117772A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- patient
- composition
- biological sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024072811A JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776253P | 2018-12-06 | 2018-12-06 | |
| US62/776,253 | 2018-12-06 | ||
| US201962840431P | 2019-04-30 | 2019-04-30 | |
| US62/840,431 | 2019-04-30 | ||
| US201962842063P | 2019-05-02 | 2019-05-02 | |
| US62/842,063 | 2019-05-02 | ||
| PCT/US2019/064190 WO2020117772A1 (en) | 2018-12-06 | 2019-12-03 | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072811A Division JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513721A JP2022513721A (ja) | 2022-02-09 |
| JPWO2020117772A5 true JPWO2020117772A5 (https=) | 2022-12-08 |
| JP2022513721A5 JP2022513721A5 (https=) | 2022-12-08 |
Family
ID=68966114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531983A Withdrawn JP2022513721A (ja) | 2018-12-06 | 2019-12-03 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
| JP2024072811A Pending JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072811A Pending JP2024096258A (ja) | 2018-12-06 | 2024-04-26 | 筋萎縮性側索硬化症における治療的介入を導くためのニューロフィラメントタンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12429487B2 (https=) |
| EP (1) | EP3890752A1 (https=) |
| JP (2) | JP2022513721A (https=) |
| KR (1) | KR20210102294A (https=) |
| CN (1) | CN113365640A (https=) |
| BR (1) | BR112021010660A2 (https=) |
| CA (1) | CA3121749A1 (https=) |
| MA (1) | MA54383A (https=) |
| MX (1) | MX2021006548A (https=) |
| WO (1) | WO2020117772A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006677XA (en) | 2018-01-25 | 2020-08-28 | Biogen Ma Inc | Methods of treating spinal muscular atrophy |
| MA54383A (fr) | 2018-12-06 | 2021-10-13 | Biogen Ma Inc | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
| CN115004350B (zh) | 2019-06-11 | 2025-10-28 | 库力索法荷兰有限公司 | 利用光学系统特性的调整的分立组件装配体的位置误差补偿 |
| US20230365937A1 (en) * | 2020-10-26 | 2023-11-16 | Hadasit Medical Research Services And Development Ltd. | Mesenchymal stem cells and their culture |
| KR200498472Y1 (ko) | 2024-05-23 | 2024-10-24 | 김민경 | 경고 또는 안내 문구를 교체형으로 구성시킬 수 있는 배수용 그레이팅 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2790034A1 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050019915A1 (en) * | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| SI2548560T1 (sl) | 2005-06-23 | 2015-12-31 | Isis Pharmaceuticals, Inc. | Sestavki in postopki za moduliranje izrezovanja smn2 |
| WO2008127974A1 (en) | 2007-04-13 | 2008-10-23 | The Trustees Of Columbia University In The City Of New York | Stem cell-based culture system for drug development |
| JP5879256B2 (ja) | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| PT3305302T (pt) | 2009-06-17 | 2018-12-14 | Biogen Ma Inc | Composições e métodos de modulação de excisões de smn2 em um sujeito |
| US8465727B2 (en) | 2009-10-06 | 2013-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biomarkers for the diagnosis of ALS |
| CA2872190C (en) | 2012-05-09 | 2024-06-25 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| HK1212597A1 (zh) | 2012-10-15 | 2016-06-17 | Isis Pharmaceuticals, Inc. | 用於調節c90rf72表達的組合物 |
| WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
| WO2014065341A1 (ja) | 2012-10-24 | 2014-05-01 | 第一三共株式会社 | 筋萎縮性側索硬化症治療剤 |
| EP2943225A4 (en) | 2013-01-09 | 2016-07-13 | Ionis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT |
| EP4166667A3 (en) | 2013-10-11 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| US20160230172A1 (en) | 2013-10-14 | 2016-08-11 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| AU2014337506B2 (en) | 2013-10-14 | 2020-10-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of C9ORF72 antisense transcript |
| WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
| CN106103717A (zh) | 2014-03-19 | 2016-11-09 | Ionis制药公司 | 用于调节共济失调蛋白2表达的组合物 |
| RS60707B1 (sr) * | 2014-04-01 | 2020-09-30 | Biogen Ma Inc | Kompozicije za modulaciju ekspresije sod-1 |
| US10024870B2 (en) | 2014-04-02 | 2018-07-17 | Wisconsin Alumni Research Foundation | Therapeutic and diagnostic methods and compositions for neurodegenerative diseases |
| WO2015161170A2 (en) | 2014-04-17 | 2015-10-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| BR112017004056A2 (pt) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo |
| KR20230104759A (ko) | 2014-09-30 | 2023-07-10 | 뉴리뮨 홀딩 아게 | 인간-유래의 항-디펩티드 반복체(dpr) 항체 |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| RS60230B1 (sr) | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| US20190002887A1 (en) | 2015-12-31 | 2019-01-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing ataxin-2 expression |
| AU2017248637A1 (en) | 2016-04-13 | 2018-09-27 | Ionis Pharmaceuticals, Inc. | Methods for reducing C9ORF72 expression |
| WO2018218219A1 (en) | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
| TW201920672A (zh) | 2017-08-08 | 2019-06-01 | 新加坡商波濤生命科學有限公司 | 寡核苷酸組合物及其使用方法 |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| SG11202006677XA (en) | 2018-01-25 | 2020-08-28 | Biogen Ma Inc | Methods of treating spinal muscular atrophy |
| EA201992364A1 (ru) | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
| BR112020021855A2 (pt) | 2018-04-27 | 2021-02-23 | Biogen Ma Inc. | anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos |
| WO2020061355A2 (en) | 2018-09-20 | 2020-03-26 | Biogen Ma Inc. | Serum neurofilament protein for guiding therapeutic intervention in multiple sclerosis |
| MA54383A (fr) | 2018-12-06 | 2021-10-13 | Biogen Ma Inc | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
| TWI906204B (zh) | 2018-12-14 | 2025-12-01 | 美商百健Ｍａ公司 | 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 |
| MA54949A (fr) | 2019-02-12 | 2021-12-22 | Biogen Ma Inc | Biomarqueurs de la leucoencéphalopathie multifocale progressive |
-
2019
- 2019-12-03 MA MA054383A patent/MA54383A/fr unknown
- 2019-12-03 KR KR1020217020744A patent/KR20210102294A/ko active Pending
- 2019-12-03 CN CN201980080522.8A patent/CN113365640A/zh active Pending
- 2019-12-03 BR BR112021010660-0A patent/BR112021010660A2/pt unknown
- 2019-12-03 US US17/299,660 patent/US12429487B2/en active Active
- 2019-12-03 EP EP19824179.6A patent/EP3890752A1/en active Pending
- 2019-12-03 MX MX2021006548A patent/MX2021006548A/es unknown
- 2019-12-03 CA CA3121749A patent/CA3121749A1/en active Pending
- 2019-12-03 JP JP2021531983A patent/JP2022513721A/ja not_active Withdrawn
- 2019-12-03 WO PCT/US2019/064190 patent/WO2020117772A1/en not_active Ceased
-
2024
- 2024-04-26 JP JP2024072811A patent/JP2024096258A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240230644A1 (en) | Methods of treating transthyretin (ttr) mediated amyloidosis | |
| JP7774960B2 (ja) | トランスサイレチン（ｔｔｒ）媒介アミロイドーシスの治療用組成物及び方法 | |
| EP3054012A1 (en) | Long non-coding RNA for the treatment of diseases associated with endothelial dysfunction | |
| JP2024518374A (ja) | トランスサイレチン（ｔｔｒ）媒介性アミロイドーシスを治療するための組成物および方法 | |
| CA2712705C (en) | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof | |
| CN105008394A (zh) | 治疗结肠直肠癌的方法 | |
| CN103958681A (zh) | 治疗非小细胞肺癌的方法 | |
| US20160272702A1 (en) | Anti-ccl8 therapy for breast cancer | |
| JPWO2020117772A5 (https=) | ||
| WO2017173327A1 (en) | Endomucin inhibitor as an anti-angiogenic agent | |
| RU2021119415A (ru) | Нейрофиламентный белок для направления терапевтических вмешательств при боковом амиотрофическом склерозе | |
| HK40063392A (en) | Methods of treating transthyretin (ttr) mediated amyloidosis | |
| HK40088348A (en) | Methods of treating transthyretin (ttr) mediated amyloidosis | |
| Yean | Maximizing Vancomycin Efficacy Through Optimal Dosing Strategy: A Comparison of Trough Concentration and Area Under the Curve-based Strategies for Achieving Therapeutic Levels. | |
| HK1240525A1 (en) | Patisiran for use in treating transthyretin mediated amyloidosis | |
| HK1240525B (en) | Patisiran for use in treating transthyretin mediated amyloidosis |